Mitochondrial electron transport chain and reactive oxygen species pathway components (ETC/ROS pathway)

The mitochondrial electron transport chain (ETC) and reactive oxygen species (ROS) pathway components represent a critical network of proteins and enzymes responsible for cellular energy production and redox homeostasis (StatPearls, 2023). The ETC consists of five multi-subunit complexes (Complex I-V) located in the inner mitochondrial membrane, which facilitate oxidative phosphorylation to generate ATP (UniProt, 2024). During this process, electron leakage, particularly at Complexes I and III, can lead to the formation of ROS, such as superoxide and hydrogen peroxide, which are further regulated by antioxidant enzymes like superoxide dismutase (SOD) and catalase (PubMed, 2021). Dysregulation of these components is a hallmark of numerous pathologies, including cancer, where metabolic reprogramming occurs, and neurodegenerative diseases like Parkinson's, characterized by mitochondrial dysfunction (NIH, 2022). Pharmacological intervention involves either inhibiting specific ETC complexes to alter metabolism (e.g., metformin targeting Complex I) or using antioxidants and NADPH oxidase (NOX) inhibitors to mitigate oxidative damage (DrugBank, 2024). However, targeting these pathways requires precision to avoid disrupting essential cellular signaling and energy production, which can lead to severe side effects like lactic acidosis or organ failure (PubMed, 2020).

Other names

Mitochondrial respiratory chainOxidative phosphorylation systemOXPHOSROS-generating enzymesMitochondrial electron transport chainReactive oxygen species pathway

Drugs targeting these components typically act by inhibiting specific complexes of the electron transport chain (e.g., Complex I inhibition by metformin), scavenging reactive oxygen species (e.g., antioxidants like MitoQ), or inhibiting ROS-producing enzymes such as NADPH oxidases (e.g., setanaxib).